Talphera, Inc. (NASDAQ:TLPH) Short Interest Up 191.0% in October

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 99,800 shares, a growth of 191.0% from the October 15th total of 34,300 shares. Based on an average trading volume of 90,600 shares, the short-interest ratio is currently 1.1 days. Approximately 0.6% of the company’s shares are short sold.

Institutional Trading of Talphera

A number of large investors have recently modified their holdings of TLPH. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Talphera during the second quarter worth $64,000. Nantahala Capital Management LLC purchased a new position in Talphera in the second quarter valued at $1,773,000. Finally, Rosalind Advisors Inc. purchased a new position in Talphera in the third quarter valued at $650,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Stock Up 5.4 %

NASDAQ:TLPH traded up $0.04 during trading hours on Friday, reaching $0.70. 58,917 shares of the stock were exchanged, compared to its average volume of 90,934. The business has a 50-day moving average of $0.89 and a two-hundred day moving average of $0.94. Talphera has a twelve month low of $0.46 and a twelve month high of $1.61. The company has a market capitalization of $11.86 million, a price-to-earnings ratio of -1.01 and a beta of 0.31.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, research analysts forecast that Talphera will post -0.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TLPH. Maxim Group upgraded Talphera to a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Talphera in a research note on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.